CSI Market
Sign In | Register

Newamsterdam Pharma N v (NAMS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access NAMS quarterly Cash Flow →
A period-by-period view of cash flow from Newamsterdam Pharma N v to helps clarify how Dec 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022)
Operating Activities
Income-203.00
Depreciation & amortization0.48
Amortization of Other Assets-1.41
Increase (Decrease) in Deferred Revenue-2.02
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property-0.01
Share-based Compensation59.43
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total13.06
Adjustments For Depreciation And Amortisation Expense-
Adjustment For Share Listing Expense-
Finance Income-
Finance Expense-
Adjustments For Sharebased Payments-
Adjustments For Decrease Increase In Other Operating Receivables-
Adjustments For Increase Decrease In Other Operating Payables-
Noncash Rent Expense-
Change In Fair Value Tranche Rights-
Change In Fair Value Of Inprocess Research And Development-
Change In Fair Value Of Derivative Earnout And Warrants18.78
Increase Decrease In Prepayments And Other Receivables-13.28
Increase Decrease In Prepayments And Other Receivables-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable4.91
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities2.45
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-147.78
Investing Activities
Capital Expenditures0.25
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities122.06
Payments to Acquire Marketable Securities296.73
Real Estate Investments0.00
Repayment Of Loan Receivable Classified As Investing Activities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-174.92
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock29.47
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.59
Transaction Costs On Issue Of Shares-
Proceeds From Payment Of Shareholder Loan-
Proceeds From Offering Of Ordinary Shares And Pre Funded Warrants Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities29.52
Effect of exchange rate on cash flow12.76
Discontinued operations0.00
Free Cash Flow-147.54
Total Cash Flow-293.18
4 historic quarters locked

Sign in to unlock the full Newamsterdam Pharma N v cash flow history.

Sign In Create Free Account

About Newamsterdam Pharma Co N v Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 18, 2026
  • Source: nams-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-056029

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License